Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058512 · ClinicalTrials.gov registry record · Phase 2
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 study, sponsored by Cellectar Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01058512 is a Phase 2 study that has completed, run by Cellectar Biosciences. The registered enrollment target is 22 participants.
The verdict
NCT01058512, a Phase 2 study, has completed, sponsored by Cellectar Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with hepatitis C.
Interventions
- DRUG NOV-205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01058512
The ClinicalTrials.gov registry entry for NCT01058512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellectar Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NOV-205 is the first listed.
NCT01058512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01058512 about?
NCT01058512 is a clinical study titled "A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy". The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with hepatitis C.
What is the current status of trial NCT01058512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2010-03. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01058512?
The interventions under investigation include: NOV-205 (DRUG).
Who is sponsoring clinical trial NCT01058512?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.